Accès gratuit
Numéro
Med Sci (Paris)
Volume 19, Numéro 1, Janvier 2003
Page(s) 43 - 53
Section M/S Revues
DOI https://doi.org/10.1051/medsci/200319143
Publié en ligne 15 janvier 2003
  1. Boon T, Brichard VG, Eynde BVD. Antigènes de rejet des tumeurs et immunothérapie spécifique du cancer. Med Sci 1995; 11: 1279–87. [Google Scholar]
  2. Eynde BJVD, Gaugler B, Probst-Kepper M, et al. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. J Exp Med 1999; 190: 1793–800. [Google Scholar]
  3. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi- Castagnoli P, Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999; 1: 362–8. [Google Scholar]
  4. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301–5. [Google Scholar]
  5. Imler J, Hoffman J. Toll receptors in innate immunity. Trends Cell Biol 2001; 11: 304–11. [Google Scholar]
  6. Delneste Y, Magistrelli G, Gauchat J, et al. Involvement of Lox-1 in dendritic cell mediated antigen cross-presentation. Immunity 2002; 17: 353–62. [Google Scholar]
  7. Banchereau J, Schuler- Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001; 106: 271–4. [Google Scholar]
  8. Barry M, Bleackley RC. Cytotoxic lymphocytes: all roads lead to death. Nat Immunol 2002; 2: 401–9. [Google Scholar]
  9. Tjelle TE, Lovdal T, Berg T. Phagosome dybnamics and function. Bioessays 2000; 22: 255–63. [Google Scholar]
  10. Grommé M, Uytdehaag FG, Janssen H, et al. Recycling MHC class I molecules and endosomal peptide loading. Proc Natl Acad Sci USA 1999; 96: 10326–31. [Google Scholar]
  11. Pittet MJ, Speiser DE, Valmori D, et al. Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients. Int Immunolpharmacol 2001; 1: 1235–47. [Google Scholar]
  12. Bonotte B, Favre N, Moutet M, et al. Bcl2-mediated inhibition of apoptosis prevents immunogenicity and restores tumorigenicity of spontaneously regressive tumors. J Immunol 1998; 161: 1433–8. [Google Scholar]
  13. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678–89. [Google Scholar]
  14. Pardoll DM. Cancer vaccines. Nat Med 1998; 4 (suppl): 525–31. [Google Scholar]
  15. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000; 101: 455–8. [Google Scholar]
  16. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997; 18: 493–7. [Google Scholar]
  17. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res 2000; 20: 2665–76. [Google Scholar]
  18. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin- 2, recombinant human interferon alpha- 2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1272–8. [Google Scholar]
  19. Mulé JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225: 1487–9. [Google Scholar]
  20. Rosenberg S, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318–21. [Google Scholar]
  21. Bouet-Toussaint F, Genetet N, Rioux-Leclercq N, et al. Interleukin 2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer. Eur Cytokine Netw 2000; 11: 217–24. [Google Scholar]
  22. Figlin R, Pierce W, Kaboo R, et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8+ selected tumor infiltrating lymphocytes from primary tumor. J Urol 1997; 158: 740–5. [Google Scholar]
  23. Dreno B, Nguyen JM, Khammari A, et al. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2002; 51: 539–46. [Google Scholar]
  24. Biragyn A, Kwak LW. Designer cancer vaccines are still in fashion. Nat Med 2000; 6: 966–8. [Google Scholar]
  25. Liau LM, Black KL, Prins RM, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 1999; 90: 1115–24. [Google Scholar]
  26. Zitvogel L, Mayodormo J, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic celles: dependence on T cells, B7 costimulation, and T helper cell-1 associated cytokines. J Exp Med 1996; 183: 87–97. [Google Scholar]
  27. Lespagnard L, Mettens P, Verheyden AM, et al. Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int J Cancer 1998; 13: 250–8. [Google Scholar]
  28. Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998; 161: 5516–24. [Google Scholar]
  29. Murphy G, Tjoa B, Ragde H, et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996; 29: 371–80. [Google Scholar]
  30. Nestlé FO, Alijagic S, Gilliet M, et al. 1998. Vaccination of melanoma patients with peptide or tumor lysatepulsed dendritic cells. Nat Med 1998; 4: 328–32. [Google Scholar]
  31. Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6: 332–6. [Google Scholar]
  32. Dudley ME, Wunderlich JR, Yang JC, et al. A phase I study of non myeloablative chemotherapy and adoptive transfer of autologous tumor-antigen specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002; 25: 243–51. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.